{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:04:23Z","timestamp":1785359063380,"version":"3.55.0"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaci.2026.06.006","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:11:14Z","timestamp":1781935874000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving landscape of JAK-STAT inhibition in the treatment of immune-mediated inflammatory diseases"],"prefix":"10.1016","author":[{"given":"Benjamin A.","family":"Turturice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Kobrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra F.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gadina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7994","key":"10.1016\/j.jaci.2026.06.006_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2026.06.006_bib2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","article-title":"JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity","volume":"155","author":"Samra","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"D1","key":"10.1016\/j.jaci.2026.06.006_bib146","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"6589","key":"10.1016\/j.jaci.2026.06.006_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jaci.2026.06.006_bib5","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1021\/acs.jmedchem.4c00197","article-title":"Functional and structural characterization of clinical-stage Janus kinase 2 inhibitors identifies determinants for drug selectivity","volume":"67","author":"Miao","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2026.06.006_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004249","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica (EAST PMR): an open-label randomized controlled trial","volume":"20","author":"Ma","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib7","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/S2665-9913(24)00270-4","article-title":"Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"7","author":"Saraux","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2026.06.006_bib9","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/art.42526","article-title":"The type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis","volume":"75","author":"Tabata","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.ajkd.2023.12.014","article-title":"APOL1 nephropathy risk variants through the life course: a review","volume":"84","author":"Itoku","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jaci.2026.06.006_bib11","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","article-title":"Baricitinib and beta-cell function in patients with new-onset type 1 diabetes","volume":"389","author":"Waibel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib12","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib13","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2202318","article-title":"Variant STAT4 and response to ruxolitinib in an autoinflammatory syndrome","volume":"388","author":"Baghdassarian","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.it.2023.12.003","article-title":"Human germline gain-of-function in STAT6: from severe allergic disease to lymphoma and beyond","volume":"45","year":"2024","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMc2001362","article-title":"Janus kinase inhibition in the Aicardi-Goutieres syndrome","volume":"383","author":"Vanderver","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib16","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s10875-023-01500-z","article-title":"JAK inhibition in Aicardi-Goutieres syndrome: a monocentric multidisciplinary real-world approach study","volume":"43","author":"Fremond","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib17","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.06.006_bib18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ard.2025.01.024","article-title":"Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases\u2014a systematic literature review informing the 2024 update of an international expert consensus statement","volume":"84","author":"Konzett","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2026.06.006_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaci.2023.10.018","article-title":"JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: an ESID\/EBMT-IEWP retrospective study","volume":"153","author":"Fischer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12969-023-00817-8","article-title":"Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS\/CANDLE, SAVI, And AGS)","volume":"21","author":"Kanazawa","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jaci.2026.06.006_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000819","article-title":"Efficacy and safety of a tofacitinib-based immunosuppressive regimen after kidney transplantation: results from a long-term extension trial","volume":"4","author":"Busque","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.jaci.2026.06.006_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.107005","article-title":"Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease","volume":"125","author":"Lebon","year":"2023","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2026.06.006_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001095","article-title":"Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis","volume":"6","author":"Harigai","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2026.06.006_bib24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib25","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2026.06.006_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ard.2025.08.028","article-title":"Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease","volume":"85","author":"Giles","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2026.06.006_bib27","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2665-9913(25)00184-5","article-title":"Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study","volume":"8","author":"Bennett","year":"2026","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2026.06.006_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2026.06.006_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1586792","article-title":"Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"16","author":"Chai","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib31","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib32","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 134","key":"10.1016\/j.jaci.2026.06.006_bib33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.55563\/clinexprheumatol\/h9gq1o","article-title":"Treatment of relapsing polychondritis: a systematic review","volume":"40","author":"Petitdemange","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib34","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib35","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jaci.2025.06.031","article-title":"IL31 identified as a key genetic risk factor for prurigo nodularis","volume":"156","author":"Patrick","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/mr\/roab030","article-title":"Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)","volume":"32","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib37","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/mr\/roac083","article-title":"Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naive to MTX treatment (FINCH 3)","volume":"33","author":"Atsumi","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2468-1253(24)00272-3","article-title":"Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn\u2019s disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"10","author":"Vermeire","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib39","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/ard-2023-224017","article-title":"Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies","volume":"82","author":"Reinisch","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2026.06.006_bib40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in active noninfectious uveitis: the HUMBOLDT randomized clinical trial","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"10162","key":"10.1016\/j.jaci.2026.06.006_bib41","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.06.006_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-089827","article-title":"Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Beh\u00e7et\u2019s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol","volume":"15","author":"Geertsema-Hoeve","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaci.2026.06.006_bib43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2026.06.006_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004857","article-title":"Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study","volume":"11","author":"Westhovens","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2026.06.006_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaci.2026.06.006_bib46","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib47","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib48","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jaip.2025.02.040","article-title":"Long-term safety of abrocitinib in moderate-to-severe atopic dermatitis: integrated analysis by age","volume":"13","author":"Cork","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.06.006_bib49","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/art.43238","article-title":"Efficacy and safety of ivarmacitinib, a selective JAK1 inhibitor, in patients with active ankylosing spondylitis: results from an adaptive seamless phase 2\/3 trial","volume":"77","author":"Liu","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib50","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jamadermatol.2025.0982","article-title":"Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial","volume":"161","author":"Zhao","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard-2024-226385","article-title":"Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial","volume":"84","author":"Liu","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2026.06.006_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2025.09.044","article-title":"Ivarmacitinib for the treatment of adults with severe alopecia areata: results from a phase 3 trial","volume":"94","author":"Zhou","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib53","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase II study","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2026.06.006_bib54","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","volume":"90","author":"Kirby","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib55","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jaad.2025.06.027","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study","volume":"93","author":"Pandya","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"6702","key":"10.1016\/j.jaci.2026.06.006_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non\u2013small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jaci.2026.06.006_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005371","article-title":"Benefit\u2013risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease","volume":"11","author":"Burmester","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2026.06.006_bib58","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","article-title":"Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"11","author":"Harrison","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaci.2026.06.006_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42918","article-title":"Efficacy and safety of pacritinib vs placebo for patients with severe COVID-19: a phase 2 randomized clinical trial","volume":"5","author":"Cafardi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaci.2026.06.006_bib60","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood.2024024789","article-title":"JAK2\/mTOR inhibition fails to prevent acute GVHD despite reduced Th1\/Th17 cells: final phase 2 trial results","volume":"144","author":"Pidala","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.06.006_bib61","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/jdv.20526","article-title":"Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: results from the ALLEGRO-LT phase 3, open-label study","volume":"39","author":"Tziotzios","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.06.006_bib62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/bjd\/ljae365","volume":"192","author":"Piliang","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib63","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/1346-8138.17442","article-title":"Efficacy and safety of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis","volume":"51","author":"Mesinkovska","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib64","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.41316","article-title":"Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib65","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/art.43184","article-title":"Efficacy and safety of zimlovisertib, ritlecitinib, and tofacitinib, alone and in combination, in patients with moderate to severe rheumatoid arthritis and an inadequate response to methotrexate","volume":"77","author":"Danto","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib66","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib67","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00403-024-03182-y","article-title":"Ritlecitinib, a JAK3\/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo","volume":"316","author":"Yamaguchi","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2026.06.006_bib68","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib69","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4685-gmb-2020-0425","article-title":"Association of TYK2 polymorphisms with autoimmune diseases: a comprehensive and updated systematic review with meta-analysis","volume":"44","author":"Pellenz","year":"2021","journal-title":"Genet Mol Biol"},{"key":"10.1016\/j.jaci.2026.06.006_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau8714","article-title":"Tuberculosis and impaired IL-23\u2013dependent IFN-\u03b3 immunity in humans homozygous for a common TYK2 missense variant","volume":"3","author":"Boisson-Dupuis","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib72","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: an open-label extension of randomized clinical trials","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib73","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s13555-023-01034-7","article-title":"Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: a network meta-analysis","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaci.2026.06.006_bib74","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2026.06.006_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.05.117","article-title":"Efficacy and safety of deucravacitinib up to week 52 from Poetyk Psa-2: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with psoriatic arthritis","volume":"84","author":"Mease","year":"2025","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.jaci.2026.06.006_bib76","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib77","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1007\/s12325-025-03299-0","article-title":"Design of two randomized, placebo-controlled, phase 3 trials of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in systemic lupus erythematosus","volume":"42","author":"Arriens","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaci.2026.06.006_bib78","article-title":"Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn\u2019s disease and ulcerative colitis","volume":"19","author":"D\u2019Haens","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2026.06.006_bib79","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljag109","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial","author":"King","year":"2026","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib80","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jid.2025.05.014","article-title":"Pharmacological characterization of zasocitinib (TAK-279): an oral, highly selective, and potent allosteric TYK2 inhibitor","volume":"146","author":"Mehrotra","year":"2026","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib81","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib82","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ard.2025.05.023","article-title":"Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study","volume":"84","author":"Kivitz","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2026.06.006_bib83","article-title":"Molecular, histological, and clinical effects of selective TYK2 inhibition with zasocitinib (TAK-279) in patients with moderate-to-severe plaque psoriasis","author":"Choudhury","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaad.2025.07.013","article-title":"Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study","volume":"94","author":"Blauvelt","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib85","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2025.10.005","article-title":"Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: results from the 52-week open-label extension period of the phase 2 STRIDE study","volume":"94","author":"Papp","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib86","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2026.06.006_bib87","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2503531","article-title":"A phase 3 trial of brepocitinib in dermatomyositis","author":"Vleugels","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib88","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib89","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300155","article-title":"Brepocitinib, zimlovisertib, and ropsacitinib in hidradenitis suppurativa","volume":"3","author":"Kimball","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jaci.2026.06.006_bib90","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib91","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaad.2024.09.073","article-title":"A phase 2a trial of brepocitinib for cicatricial alopecia","volume":"92","author":"David","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib92","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/bjd\/ljad098","article-title":"Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study","volume":"189","author":"Landis","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib93","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bjd.21826","article-title":"Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study","volume":"187","author":"Landis","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib94","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","article-title":"Discovery of tyrosine kinase 2 (TYK2) inhibitor (PF-06826647) for the treatment of autoimmune diseases","volume":"63","author":"Gerstenberger","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2026.06.006_bib95","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib96","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/epi.16848","article-title":"Tofacitinib treatment for refractory autoimmune encephalitis","volume":"62","author":"Jang","year":"2021","journal-title":"Epilepsia"},{"issue":"7 suppl 1","key":"10.1016\/j.jaci.2026.06.006_bib97","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/WNL.0000000000208701","article-title":"BHV-8000, a selective brain-penetrant TYK2\/JAK1 inhibitor in development for neuroinflammatory and neurodegenerative diseases, demonstrates efficacy in an alpha-synuclein overexpressing Parkinson\u2019s disease mouse model (S4.006)","volume":"104","author":"Liang","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2026.06.006_bib98","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1021\/acs.jmedchem.4c00769","article-title":"Discovery of GLPG3667, a selective ATP competitive tyrosine kinase 2 inhibitor for the treatment of autoimmune diseases","volume":"67","author":"Mammoliti","year":"2024","journal-title":"J Med Chem"},{"issue":"suppl 9","key":"10.1016\/j.jaci.2026.06.006_bib99","article-title":"In vitro pharmacological profile of GLPG3667 suggests differentiation from the TYK2 inhibitors deucravacitinib and zasocitinib at their clinical dose regimens","volume":"77","author":"Lepage","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib100","article-title":"Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA","volume":"13","author":"Mustapa","year":"2026","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.jaci.2026.06.006_bib101","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaci.2021.08.013","article-title":"JAK inhibitors for asthma","volume":"148","author":"Georas","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib102","article-title":"Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial","volume":"10","author":"Belperio","year":"2023","journal-title":"BMJ Open Respir Res"},{"issue":"suppl 1","key":"10.1016\/j.jaci.2026.06.006_bib103","doi-asserted-by":"crossref","first-page":"i505","DOI":"10.1093\/ecco-jcc\/jjac190.0505","article-title":"P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn\u2019s disease: a phase 2 double-blind, randomized, placebo-controlled study","volume":"17","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2026.06.006_bib104","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/bcp.70262","article-title":"AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma","volume":"92","author":"Lundahl","year":"2026","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2026.06.006_bib105","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaci.2021.02.042","article-title":"Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial","volume":"148","author":"Braithwaite","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib106","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12931-025-03309-3","article-title":"ARTEMISIA: a mechanistic study of a novel Janus kinase 1 inhibitor to advance molecular understanding and precision medicine in asthma","volume":"26","author":"Dosanjh","year":"2025","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2026.06.006_bib107","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ado5986","article-title":"An activating Stat1 mutant disrupts normal STAT4 innate lymphocyte programs during viral infection","volume":"10","author":"Philips","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade7028","article-title":"Dysregulated IFN-\u03b3 signals promote autoimmunity in STAT1 gain-of-function syndrome","volume":"15","author":"Largent","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1183273","article-title":"The human STAT1 gain-of-function T385M mutation causes expansion of activated T-follicular helper\/T-helper 1\u2013like CD4 T cells and sex-biased autoimmunity in specific pathogen-free mice","volume":"14","author":"Scott","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib111","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/intimm\/dxz079","article-title":"Human gain-of-function STAT1 mutation disturbs IL-17 immunity in mice","volume":"32","author":"Tamaura","year":"2020","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib112","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2026.06.006_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055718","volume":"12","author":"Nishina","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaci.2026.06.006_bib114","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST Platform trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaci.2026.06.006_bib115","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","article-title":"Phase I trial of TTI-101, a first-in-class oral inhibitor of STAT3, in patients with advanced solid tumors","volume":"31","author":"Tsimberidou","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2026.06.006_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112977","article-title":"Therapeutic potential of a small-molecule STAT3 inhibitor in a mouse model of colitis","volume":"15","author":"Robinson","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaci.2026.06.006_bib117","article-title":"REX-7117 is a highly potent and selective oral STAT3 inhibitor that demonstrated potential efficacy and safety differentiation versus JAK\/TYK2 targeting in preclinical models of inflammatory arthritis","volume":"76","author":"Gardino","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib118","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaci.2026.06.006_bib119","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-025-01674-6","article-title":"Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024","volume":"18","author":"Li","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jaci.2026.06.006_bib120","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1021\/acs.jmedchem.2c01665","article-title":"Discovery of a potent and selective STAT5 PROTAC degrader with strong antitumor activity in vivo in acute myeloid leukemia","volume":"66","author":"Kaneshige","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2026.06.006_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2024.08.193","article-title":"Potent and selective oral STAT6 degrader KT-621 inhibits IL-4\/IL-13 in mouse models of asthma","volume":"133","author":"Wang","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib122","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1021\/acs.jmedchem.4c01009","article-title":"Discovery of AK-1690: a potent and highly selective STAT6 PROTAC degrader","volume":"68","author":"Kaneshige","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2026.06.006_bib123","article-title":"Discontinuation syndrome with JAK2 selective agents: case presentation and mechanistic insights","volume":"8","author":"Handa","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jaci.2026.06.006_bib124","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.chembiol.2023.05.007","article-title":"New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation","volume":"30","author":"Arwood","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.jaci.2026.06.006_bib125","doi-asserted-by":"crossref","first-page":"31471","DOI":"10.1182\/blood-2024-193905","volume":"144","author":"Mascarenhas","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.06.006_bib126","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41589-022-01098-0","article-title":"Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine","volume":"18","author":"Kavanagh","year":"2022","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jaci.2026.06.006_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2024.101072","article-title":"Molecular basis of JAK kinase regulation guiding therapeutic approaches: evaluating the JAK3 pseudokinase domain as a drug target","volume":"95","author":"Virtanen","year":"2025","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.jaci.2026.06.006_bib128","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.06.006_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103440","article-title":"Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: a systematic review and meta-analysis","volume":"22","author":"Ma","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2026.06.006_bib130","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003991","article-title":"Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus","volume":"10","author":"Satoh-Kanda","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2026.06.006_bib131","article-title":"TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation","volume":"6","author":"Tuomela","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jaci.2026.06.006_bib132","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/art.43210","article-title":"Paradoxical activation of entheseal myeloid cells by JAK1 and Tyk2 inhibitors via interleukin-10 antagonism","volume":"77","author":"Giryes","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib133","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1097\/RHU.0000000000001767","article-title":"Combination therapy with tofacitinib and IL-12\/23, IL-23, or IL-17A inhibition for the treatment of refractory psoriatic arthritis: a case series","volume":"28","author":"Shurey","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib134","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1136\/ard-2024-225800","article-title":"Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series","volume":"83","author":"Hren","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2026.06.006_bib135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41927-024-00373-y","article-title":"The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study","volume":"8","author":"Chang","year":"2024","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib136","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/jdv.20132","article-title":"Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis","volume":"39","author":"De Greef","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.06.006_bib137","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdcr.2021.01.020","article-title":"Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy","volume":"10","author":"Peterson","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2026.06.006_bib138","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/bjd.21776","article-title":"Dupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumab","volume":"187","author":"Yang","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib139","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jdcr.2023.01.020","article-title":"JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: a case series of 6 patients","volume":"33","author":"Shahriari","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2026.06.006_bib140","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/RHU.0000000000000663","article-title":"A case series on patients on tofacitinib in combination with a biologic","volume":"24","author":"Barroso","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaci.2026.06.006_bib141","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15311","article-title":"A retrospective study of efficacy of tofacitinib combined with bDMARDs in the treatment of rheumatoid arthritis patients with inadequate response to bDMARDs","volume":"27","author":"Chang","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaci.2026.06.006_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152660","article-title":"Combotherapies in immune-mediated inflammatory diseases: a study using the Clinical Data Warehouse from Paris hospitals\u2019 public assistance","volume":"71","author":"Gerard","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaci.2026.06.006_bib143","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.4049\/jimmunol.1801473","article-title":"The neuroimmune axis in skin sensation, inflammation, and immunity","volume":"202","author":"Trier","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2026.06.006_bib144","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.immuni.2025.03.018","article-title":"The sensory neuroimmune frontier","volume":"58","author":"Kim","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2026.06.006_bib145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.43014","article-title":"Effectiveness of JAK inhibitors compared with biologic disease-modifying antirheumatic drugs on pain reduction in rheumatoid arthritis: results from a nationwide Swedish cohort study","volume":"77","author":"Eberhard","year":"2025","journal-title":"Arthritis Rheumatol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926004380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926004380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:41:51Z","timestamp":1785357711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926004380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":146,"alternative-id":["S0091674926004380"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.06.006","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving landscape of JAK-STAT inhibition in the treatment of immune-mediated inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}